Jury finds Lilly breaches implied covenant in rezpegaldesleukin license, awards Nektar USD 90 million plus interest
Bitget2026/09/25 11:01- A U.S. jury found Lilly breached the implied covenant of good faith in a rezpegaldesleukin license agreement with Nektar Therapeutics.
- The verdict followed a jury trial that began Sept. 8, 2026 in federal court in Northern California.
- Damages were set at USD 90 million, with interest to be determined by the court.
- Post-trial motions remain pending. Any final judgment could face appeal.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Altman: Safety comes first, no IPO timetable, postponing the release of GPT-6.1 Astra out of extreme caution
OpenAI CEO Altman stated that the IPO may only be considered after the company gains a clearer understanding of how to safely manage the "next-level AI." The delay in launching GPT-6.1 Astra is because the model did not meet some of the company’s evaluation criteria for safety; this decision was made "out of an abundance of caution" rather than due to any major incident. He also noted that Nvidia’s safety systems for AI are not a "complete solution;" AI is more of a scientific problem than an engineering one.
Talen names Terry Nutt CEO effective Jan. 1, 2027; Mac McFarland retires at year-end
Fed's Barr Renews Rate Increase Calls; New York Fed Chief Says Next Hike Can Wait